



*Jubilant DraxImage Radiopharmacies Inc.
790 Township Line Rd., Suite 175
Yardley, PA 19067*

September 21, 2017

VIA OVERNIGHT MAIL & EMAIL (patricia.pelke@nrc.gov)

Patricia Pelke, Chief, Materials Licensing Branch
United States Nuclear Regulatory Commission
Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532

**Re: Change of Control and Transfer of Radioactive Material License Nos.
09-32781-01MD, -02MD, -03MD, and -04MD**

Dear Ms. Pelke:

This letter is in regard to the request for Change of Control and Transfer of Radioactive Material License ("RAML") Nos. 09-32781-01MD, -02MD, -03MD, and -04MD from Triad Isotopes, Inc. ("Triad") to Jubilant DraxImage Radiopharmacies Inc. ("Jubilant").

As background, Triad and Jubilant entered into an Asset Purchase Agreement on May 4, 2017, whereby Jubilant agreed to purchase substantially all of the assets of Triad (the "Transaction"). The closing of that Transaction was subject to customary closing conditions, including the receipt of required contractual and regulatory approvals.

Pursuant to Section 184 of the Atomic Energy Act of 1954, 42 U.S.C. §2234, and NUREG-1556, Vol. 15, Rev. 1, Triad and Jubilant submitted to the Commission an initial letter dated May 24, 2017 requesting the Commission's consent to the transfer of control of the above-referenced RAMLs. Triad received from the Commission a letter and Safety Evaluation Report dated August 28, 2017 consenting to the transfer of the above RAMLs. Triad additionally received a revised letter and Safety Evaluation Report dated August 31, 2017, also consenting to the transfer.

Pursuant to the email correspondence sent by Jared Heck, NRC Region III Regional Counsel, to legal counsel for Triad and Jubilant on September 1, 2017, this letter is to notify the Commission that the Transaction has now closed, effective September 1, 2017.

Please amend the above RAMLs to reflect the change of control and transfer consistent with the above-referenced date of the Closing. Please note, Jubilant DraxImage Radiopharmacies Inc. intends to operate under the name "Jubilant DraxImage Radiopharmacies Inc., d/b/a Triad Isotopes." However, Assumed Name filings in the State of Michigan are still pending.

Accordingly, please amend RAMLs 09-32781-01MD and 09-32781-04MD in the name of "Jubilant DraxImage Radiopharmacies Inc., d/b/a Triad Isotopes" and please amend RAMLs 09-32781-02MD and 09-32781-03MD in the name of "Jubilant DraxImage Radiopharmacies Inc." Jubilant will provide an additional request to amend the name for -02MD and -03MD once the d/b/a filing in Michigan is complete.

RECEIVED SEP 22 2017



*Jubilant DraxImage Radiopharmacies Inc.
790 Township Line Rd., Suite 175
Yardley, PA 19067*

Thank you for your attention to this matter.

Sincerely,

Thomas Rafferty, VP/General Manager
Jubilant DraxImage Radiopharmacies Inc.

cc: Colleen Casey, Materials Licensing Reviewer, NRC Region III (*via email*)
Jared Heck, Esq., Regional Counsel, NRC Region III (*via email*)
James Wilkinson, Esq., VP Legal, Jubilant DraxImage Radiopharmacies Inc. (*via email*)
Craig S. Kinne, Corporate RSO, Jubilant DraxImage Radiopharmacies Inc. (*via email*)

ORIGIN ID: ORLA (407) 257-8998
 JAMES A. WILKINSON
 TRIAD ISOTOPES INC
 4205 VINELAND ROAD
 SUITE L1
 ORLANDO, FL 32811
 UNITED STATES US

SHIP DATE: 21SEP17
 ACTWGT: 0.50 LB
 CAD: 107378901/INET3920

BILL SENDER


TO **PATRICIA PELKE**
US NUCLEAR REGULATORY COMMISSION
2443 WARRENVILLE RD STE 210
MATERIALS LICENSING
LISLE IL 60532

(407) 455-6717

REF: LEGAL

INV.
 PO:

DEPT:



J17211708130100

TRK#
 0201


7703 1232 2662

FRI - 22 SEP 3:00P
 STANDARD OVERNIGHT

XH ENLA

IL-US

60532
 ORD



RECEIVED SEP 22 2017

549J1FF19104C

After printing this label:

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number. Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$1,000, e.g. jewelry, precious metals, negotiable instruments and other items listed in our ServiceGuide. Written claims must be filed within strict time limits, see current FedEx Service Guide.